SCHEMBL2279243

SCHEMBL2279243

C=CCc1cccc(-c2[nH]c3cc(C(=O)OC)ccc3c2C2CCCCC2)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.41
KIF11 P52732 1/20 0.41
HPGD P15428 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
PPM1D O15297 2/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPK1 P28482 2/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 3/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
GSK3B P49841 2/20 0.35
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
MDH2 P40926 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3684108 0.95 PARP1 (0.38) PARP1KIF11HPGDGABRA1GABRB2
SCHEMBL3685197 0.92 PARP1 (0.38) PARP1KIF11HPGDPPM1DALDH1A1
SCHEMBL2277016 0.88 PARP1 (0.43) PARP1KIF11HPGDPPM1DALDH1A1
SCHEMBL2277324 0.85 PDGFRB (0.43) PARP1KIF11HPGDALDH1A1MAPK1
SCHEMBL3793445 0.85 PARP1 (0.47) PARP1KIF11HPGDALDH1A1MAPK1
SCHEMBL2276592 0.84 PARP1 (0.44) PARP1KIF11HPGDALDH1A1MAPK1
SCHEMBL2274667 0.84 PARP1 (0.46) PARP1KIF11HPGDALDH1A1MAPK1
SCHEMBL3590838 0.84 PARP1 (0.50) PARP1KIF11HPGDALDH1A1MAPK1
SCHEMBL14253832 0.84 PARP1 (0.50) PARP1KIF11HPGDALDH1A1MAPK1
SCHEMBL771987 0.82 PARP1 (0.48) PARP1KIF11HPGDALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989438-B2 Therapeutic compounds ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2011-08-02 US disclosed
EP-2178885-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2010-04-28 EP disclosed
US-20090048239-A1 Therapeutic compounds MSD ITALIA S.R.L. (IT) 2009-02-19 US disclosed
WO-2009010783-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048239-A1 Therapeutic compounds RRP1B, RCE1, CTSZ PARP1 1571/4885KIF11 3194/4885HPGD 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.